At the outset, we would like to congratulate that Kas Medics forayed into Biopharma segment and got registered a blockbuster molecule in Tanzania called “Rituximab” in the name of Rilast brand, a product from Hetero Biopharma.
Kas Medics have conducted a successful CME at ORCI (Ocean Road Cancer Institute – Dar Es Salaam) on 12th Sep’18.
Dr Jerry, Associate Director ORCI, delivered his lecture about high science at Rituximab, its mode of action and indication of doses in the cancer patients. Dr Jerry and his team of 70 people of ORCI attended this high science session with a hunger of curiosity to know more about Rituximab.
Mabthera (Roche Brand) is our strong competitor in this segment. Nonetheless, we offer a very lucrative price than Mabthera. Huge Thanks to Mr Nishitha for putting his efforts for the last 2 years to get it registered from TFDA.
Jawan Shekhawat, Business Development Manager – Formulations & Joyce Sanga, Marketing Manager – Kas Medics put their endeavour to make it a successful CME.
The good news is, Kas Medics already got the first order just after the next day of registration from ORCI.
We, at Kas Medics, are highly optimistic about Rilast. Doctors are excited to use this product. We have changed the perception of the market; we are a science-driven company, where commerce follows the science.
One More wonderful molecule we have in our portfolio – DERISE. A unique product in Nephrology segment to change the blood picture of CRF patients.
Leave a Reply